Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥40 years old.~* Resting ankle-brachial index (ABI) ≤0.90 in the limiting leg(s), or a \>20% reduction in the ABI measured immediately post-exercise where the resting ABI is \>0.90. In cases of incompressible arteries in the limiting leg(s) (i.e. ABI ≥1.40), a toe-brachial index (TBI) of ≤0.70 is required.~* Peripheral artery stenosis/occlusion in the limiting leg(s), documented by duplex ultrasonography or other imaging tests.~* Stable (i.e. 3-month history) intermittent claudication in at least one PAD-affected leg.~* Maximum walking time during graded treadmill exercise testing (Gardner-Skinner protocol) ≥1 minute and ≤16 minutes.~* Concurrent medications that may affect primary, secondary or exploratory endpoints have remained stable over the previous 3 months.~* Have given signed informed consent to participate in the study.~Exclusion Criteria:~* Identification of any other medical condition requiring immediate therapeutic intervention.~* Clinically significant abnormal electrocardiogram (ECG) at rest or during exercise that represents a contraindication to study procedures or the study drug.~* Myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft surgery (CABG), or other major surgery within the previous 6 months.~* Exercise capacity limited by a factor other than PAD-related intermittent claudication.~* Any condition that precludes valid completion of a treadmill exercise test.~* Critical limb ischemia in either leg, defined as PAD-related chronic ischemic rest pain or skin lesions (ulcers, gangrene).~* Previous peripheral revascularisation or other surgical treatment for PAD in the previous 6 months.~* Known non-atherosclerotic cause of PAD.~* Active cancer.~* Uncontrolled hypertension (resting brachial blood pressure ≥160/100 mmHg).~* Evidence of pharmacologically-treated or poorly controlled (i.e. HbA1c ≥7.5%) type 2 diabetes or other class of diabetes (e.g. type 1 diabetes).~* Known intolerance or contraindication(s) to metformin.~* Known contraindication(s) to Definity (perflutren lipid microsphere).~* Participation or intention to participate in another clinical research study during the study period.~* History of non-compliance to medical regimens or unwillingness to comply with the study protocol.~* Any other condition that in the opinion of the Investigators would confound the evaluation and interpretation of the data.~* Persons directly involved in the execution of the protocol.~* Incapable of providing written informed consent due to cognitive, language, or other reasons.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e. maximum of 2000mg per day).
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo twice daily for 16-18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).